Literature DB >> 7724185

Scleritis associated with systemic vasculitic diseases.

M Sainz de la Maza1, C S Foster, N S Jabbur.   

Abstract

PURPOSE: Scleritis may occur associated with systemic vasculitic diseases. The detection of systemic vasculitic diseases in patients with scleritis is a sign of poor general prognosis because it indicates potentially lethal systemic complications. This study was undertaken to analyze the ocular prognosis of patients with scleritis and the different systemic vasculitic diseases.
METHODS: Patient characteristics, scleritis type, and ocular complications were evaluated in 82 patients with scleritis with systemic vasculitic diseases; comparisons were made between patients with scleritis with a specific systemic vasculitic diseases and patients with scleritis with the other systemic vasculitic diseases.
RESULTS: Patients with scleritis with Wegener granulomatosis had more necrotizing scleritis (79%, P = 0.0001), decrease in vision (79%, P = 0.014), and peripheral ulcerative keratitis (50%, P = 0.0139) than patients with scleritis with the other systemic vasculitic diseases. Patients with scleritis with spondyloarthropathies had less decrease in vision (8%, P = 0.001) and peripheral ulcerative keratitis (0%, P = 0.0256) than patients with scleritis with the other systemic vasculitic diseases. Patients with scleritis and systemic lupus erythematosus had less necrotizing scleritis (0%, P = 0.0412) than patients with scleritis with the other systemic vasculitic diseases.
CONCLUSIONS: Ocular prognosis of scleritis with systemic vasculitic diseases varies depending on the specific systemic vasculitic diseases: scleritis in spondyloarthropathies or in systemic lupus erythematosus is usually a benign and self-limiting condition, whereas scleritis in Wegener granulomatosis is a severe disease that can lead to permanent blindness; scleritis in rheumatoid arthritis or relapsing polychondritis is a disease of intermediate severity, which should be monitored closely for the development of ocular complications.

Entities:  

Mesh:

Year:  1995        PMID: 7724185     DOI: 10.1016/s0161-6420(95)30970-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  27 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts.

Authors:  N Di Girolamo; A Lloyd; P McCluskey; M Filipic; D Wakefield
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  Complications of misdiagnosed and inadequately treated necrotizing scleritis studied by ultrasound biomicroscopy and computerized corneal topography.

Authors:  D Meller; T Böker
Journal:  Int Ophthalmol       Date:  1997       Impact factor: 2.031

4.  Haemophilus influenzae associated scleritis.

Authors:  S O Sykes; C Riemann; C I Santos; D M Meisler; C Y Lowder; J P Whitcher; E T Cunningham
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

Review 5.  [Diagnosis and treatment of episcleritis and scleritis].

Authors:  C Tappeiner; K Walscheid; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2016-09       Impact factor: 1.059

6.  Identification of multipotent stem/progenitor cells in murine sclera.

Authors:  Chia-Ling Tsai; Pei-Chang Wu; M Elizabeth Fini; Songtao Shi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-25       Impact factor: 4.799

Review 7.  Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

Review 8.  Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations.

Authors:  Buraa Kubaisi; Khawla Abu Samra; C Stephen Foster
Journal:  Intractable Rare Dis Res       Date:  2016-05

9.  Five-year outcome in immune-mediated scleritis.

Authors:  Wolfgang Bernauer; Beat Pleisch; Matthias Brunner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-10       Impact factor: 3.117

10.  Visual loss from scleritis in C-ANCA-positive microscopic polyangiitis.

Authors:  Salah Alrashidi; Yacoub A Yousef; Hatem Krema
Journal:  BMJ Case Rep       Date:  2013-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.